Advertisement

Oral Polio Vaccine and the Results of Its Use

  • Joseph Melnick
Chapter

Abstract

Reports on clinical and epidemiological aspects of poliomyelitis came in the late nineteenth and early twentieth centuries from von Heine, Medin, and Wickman in Europe, and Caverly in the USA, but basic studies on poliovirus only began in 1908 when Landsteiner, Popper, and Levaditi, again in Europe, transmitted the disease to monkeys, inducing typical histopathology lesions in the animals spinal cords. Shortly thereafter, Flexner and Wollstein in the USA achieved monkey-to-monkey passage.

Keywords

Cynomolgus Monkey Inactivate Poliovirus Vaccine Paralytic Poliomyelitis Wild Poliovirus Polio Case 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Paul JR. A History of Poliomyelitis. New Haven, CT: Yale University Press, 1971Google Scholar
  2. 2.
    Melnick JL. Poliomyelitis virus in urban sewage in epidemic and nonepidemic times. Am J Hyg 1947;45:240–53PubMedGoogle Scholar
  3. 3.
    Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues. Science 1949;109:85–87PubMedCrossRefGoogle Scholar
  4. 4.
    Melnick JL, Horstmann DM. Active immunity to poliomyelitis in chimpanzees following subclinical infection. J Exp Med 1947;85:287–303PubMedCrossRefGoogle Scholar
  5. 5.
    von Magnus H, Melnick JL. Antibody response in monkeys following oral administration of poliomyelitis virus. J Immunol 1948;60:583–596Google Scholar
  6. 6.
    Bodian D, Horstman DM. Polioviruses. In: Horsfall FL, Tamm I eds. Viral and Rickettsial Infection of Man, 4th ed, Philadelphia: Lippincott, 1965;430–473Google Scholar
  7. 7.
    Melnick JL, Ledinko N. Development of neutralizing antibodies against the three types of poliomyelitis virus during an epidemic period. The ratio of inapparent infection to clinical poliomyelitis. Am J Hyg 1953;58:207–222Google Scholar
  8. 8.
    Brodie M, Park WH. Active immunization against poliomyelitis. Am J Public Health 1936; 26:119.Google Scholar
  9. 9.
    Kolmer JA. Vaccination against acute anterior poliomyelitis. Am J Public Health 1936; 26:126.Google Scholar
  10. 10.
    Robbins FC. The history of polio. Chapter 2 in Vaccines, 4th ed. Editors: Plotkin SA and Orenstein WA, Offit, PA. Saunders, Philadelphia, 2004:17–30Google Scholar
  11. 11.
    Koprowski HL, Jervis GA, Norton TW. Immune responses in human volunteers upon oral administration of a rodent-adapted strain of poliomyelitis. Am J Hyg 1952;55:108–126PubMedGoogle Scholar
  12. 12.
    Cabasso VJ, Jervis GA, Moyer AW, Roca-Garcia M, Orsi EV, Cox HR. Cumulative testing experience with consecutive lots of oral poliomyelitis vaccine. In: Live Polio Virus Vaccine. PAHO: Washinton DC, 1959:102–134Google Scholar
  13. 13.
    Dulbecco R, Vogt M. Biological properties of poliomyelitis viruses as studied by the plaque technique. Ann NY Acad Sci 1996;61:790–800CrossRefGoogle Scholar
  14. 14.
    Sabin AB, Hennessen WA, Winsser J. Studies on variants of poliomyelitis virus: experimental segregation and properties of avirulent variants of three immunologic types. J Exp Med 1954;99:551–576PubMedCrossRefGoogle Scholar
  15. 15.
    Sabin AB. Immunization of chimpanzees and human beings with avirulent strains of poliomyelitis virus. Ann NY Acad Sci 1955;61:1050–1056PubMedCrossRefGoogle Scholar
  16. 16.
    Sabin AB. Behavior of chimpanzees avirulent poliomyelitis viruses in experimentally infected human volunteers. Am J Med Sci 1962;230:1–8CrossRefGoogle Scholar
  17. 17.
    Sabin AB. Recent studies and field tests with a live attenuated poliovirus vaccine. First Inst Conf on Live Poliovirus Vaccines, Washington, DC, 1959:14–38Google Scholar
  18. 18.
    Chumakov MP, Voroshilova MK, Vasileva KA et al. Preliminary report on mass oral immunization of population against poliomyelitis with live virus vaccine from Sabin’s attenuated strains. First Int. Conf. on Live Poliovirus Vaccines, Washington, DC, 1959:517–621Google Scholar
  19. 19.
    Sabin AB. Status of field trials with an orally administered, live attenuated poliovirus vaccine. J Am Med Assoc. 1959;17:863–868Google Scholar
  20. 20.
    Melnick JL, Brennan JC. Monkey neurovirulence of attenuated poliovirus vaccines being used in field trials. In: Live Polio Vaccine. PAHO: Washinton DC, 1959:65–101Google Scholar
  21. 21.
    Murray R, Kirschstein G, Van Hoosier G, Baron S. Comparative virulence for rhesus monkeys of poliovirus strains used for oral administration. In: Live Polio Vaccine. PAHO: Washinton DC, 1959:39–64Google Scholar
  22. 22.
    Sabin AB. Recent studies and field tests with live attenuated poliovirus vaccine. In: Live Polio Vaccine. PAHO: Washinton DC, 1959:33Google Scholar
  23. 23.
    Sabin AB. Paralytic poliomyelitis: Old dogmas and new perspectives Rev Infect Dis 1981;3:543–564Google Scholar
  24. 24.
    Melnick JL. Live attenuated and disadvantages of killed and live poliomyelitis vaccines. Bull WHO 1978;56:21–38PubMedGoogle Scholar
  25. 25.
    Salk J, Drucker J. Noninfectious poliovirus vaccine. In: Plotkin SA, Mortimer EA Jr., eds. Vaccines, 2nd ed, Philadelphia: WB Saunders, 1993;14–38Google Scholar
  26. 26.
    van Wezel AL, van Steenis G, van der Marel P, Osterhaus ADME. Inactivated poliovirus ­vaccine: current production methods and new developments. Rev Infect Dis 1984; 6 (suppl 2): S335–S340PubMedCrossRefGoogle Scholar
  27. 27.
    Melnick JL. Live attenuated poliovaccines. In: Plotkin SA, Mortimer EA Jr., eds. Vaccines, 2nd ed, Philadelphia: WB Saunders, 1993;155–204Google Scholar
  28. 28.
    Melnick JL. Population genetics applied to live poliovirus vaccine. Am J Public Health 1962;52:472–483CrossRefGoogle Scholar
  29. 29.
    Melnick JL. Variation in poliomyelitis virus on serial passage through tissue culture. Cold Spring Harbor Symp Quant Biol 1953;18:178–179Google Scholar
  30. 30.
    Nomoto A, Wimmer E. Genetic studies of the antigenicity and the attenuation phenotype of poliovirus. In: Russell WC, Almond JW, eds. Molecular Basis of Virus Disease 1987;107–134Google Scholar
  31. 31.
    Benyesh-Melnick M, Melnick JL, Rawls WE, Wimberly I, Barrera Oro J, Ben-Porath E, Rennick V. Studies of the immunogenicity, commincability and genetic stability of oral poliovirus administered during the winter. Am J Epidemiol 1967;86:112–136Google Scholar
  32. 32.
    Rico-Hesse R, Pallansch MA, Nottay BK, Kew OM. Geographic distribution of wild ­poliovirus type 1 genotypes. Virology 1992;160:311–322CrossRefGoogle Scholar
  33. 33.
    Rezapkin GV, Chumakov KM, Zhengbin LU, Yuxin R, Dragunsky EM, Levenbrook IS. Microevolution of Sabin 1 in vitro and genetic stability of oral poliovirus vaccine. Virology 1994;202:370–378PubMedCrossRefGoogle Scholar
  34. 34.
    McGoldrick A, Macadam AJ, Dunn G et al. Role of mutations G-480 and C-6203 in the Attenuation Phenotype of Sabin Type 1 Poliovirus. J Virol 1995;69:7601–7605PubMedGoogle Scholar
  35. 35.
    Ren R, Racaniello VR. Human poliovirus receptor gene expression and poliovirus tissue ­tropism in transgenic mice. J Virol 1992;66:296–304PubMedGoogle Scholar
  36. 36.
    Abe S, Yoshihiro O, Koike S, Kurata T, Horie H, Nomura T, Hashizume S, Nomoto A. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice. Virology 1995;206:1075–1083PubMedCrossRefGoogle Scholar
  37. 37.
    Assaad FA. The relation between acute persisting spinal paralysis and poliomyelitis vaccine (oral): results of a WHO inquiry. Bull WHO 1976;53:319–331Google Scholar
  38. 38.
    World Health Organization. Poliomyelitis in 1985–1989. Weekly Epidemiological Record 1987;62:273–280, 1989;64:273–279, 1991;66:49–53, 70–72Google Scholar
  39. 39.
    Melnick JL, Ashkenazisa A, Midulla VC, Berstein A. Immunogenic potency of MgCl2 –stabilized oral poliovaccine. JAMA 1963;185:406–408PubMedGoogle Scholar
  40. 40.
    Crainic R. Stabilization of Vaccine by Dueterion Ovide. WHO Task Force on Vaccines, 1995Google Scholar
  41. 41.
    de Quadros CA, Henderson DA. Disease eradication and control in the Americas. Biologicals 1993;21:335Google Scholar
  42. 42.
    Von Magnus H, Peterson I. Vaccination with inactivated poliovirus vaccine and oral poliovirus vaccine in Denmark. Rev Infect Dis 1984;6:S471–S474CrossRefGoogle Scholar
  43. 43.
    Lasch EE, Abed Y, Abdulla K et al. Successful results of a program combining live and inactivated poliovirus vaccines to control poliomyelitis in Gaza. Rev Infect Dis 1984;6:S467–S470PubMedCrossRefGoogle Scholar
  44. 44.
    Goldblum N, Gerichter CB, Tulchinsky TH, Melnick JL. Poliomyelitis control in Israel, the West Bank and Gaza Strip: changing strategies with the goal of eradication in an endemic area. Bull WHO 1994;72:783–796PubMedGoogle Scholar
  45. 45.
    Slater PE, Orenstein WA, Morag A et al. Poliomyelitis outbreak in Israel in 1988: a report with two commentaries. Lancet 1990;335:1192–1198PubMedCrossRefGoogle Scholar
  46. 46.
    Minor PD. The molecular biology of poliovaccines. J Gen Virol 1992;74:3065–3077CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Joseph Melnick
    • 1
  1. 1.HoustonUSA

Personalised recommendations